Then-acting FDA leaders said over the summer that regulatory flexibility wasn’t the standard they were striving for when the agency gauges rare disease drugs.
Now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.